Common painkiller could boost immunotherapy in advanced lung cancer

NCT ID NCT06731270

Recruiting now Disease control Sponsor: Emory University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial tests whether adding diclofenac, a common anti-inflammatory painkiller, can help control advanced non-small cell lung cancer when immunotherapy alone starts to show signs of failing. About 20 adults whose cancer has progressed while on standard immunotherapy drugs like pembrolizumab or atezolizumab will receive diclofenac alongside their current treatment. The goal is to see if this combination can shrink tumors or slow the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: diclofenac
What this could lead to: If it works, this could offer a way to extend the benefit of immunotherapy for people with advanced lung cancer, potentially delaying disease progression.
What could go wrong: This is a small, early-phase trial with only 20 participants, so results may not apply broadly. Diclofenac also has known risks like stomach bleeding and kidney issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED LUNG NON-SMALL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED LUNG NON-SMALL CELL CARCINOMA METASTATIC LUNG NON-SMALL CELL CARCINOMA STAGE III LUNG CANCER AJCC V8 STAGE IV LUNG CANCER AJCC V8

Contacts and locations

Locations

Emory University Hospital Midtown
RECRUITING

Atlanta, Georgia, 30308, United States
Emory University Hospital/Winship Cancer Institute
RECRUITING

Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.